MeiraGTx Holdings plc

MeiraGTx Holdings plc

MGTXNYSE / NASDAQHealthcareSmall cap

$7.98-$0.16 (-2.0%)

Last close · Data as of Nov 20, 2026

Market cap
$886.3M
P/E
-7.8x
EV / EBITDA
-10.2x
Revenue
$81.4M
Net margin
-140.3%
ROCE
-86.9%

+7.4% over the last year

MeiraGTx Holdings plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-20.0%
3M
-45.1%
6M
-16.7%
1Y
+7.4%
5Y
-57.2%

52-week range

Day change -$0.16 (-2.0%) from $8.14 to $7.98 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MGTX, bought on each weekday since 2021.

News & filings

What MeiraGTx Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Read moreShow less

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Sector
Healthcare
Shares outstanding
81.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$886.3M
P/E
-7.8x
P/B
-153.0x
EV / EBITDA
-10.2x
EV / Sales
11.2x
P/S
10.9x
52-week high
$14.97
52-week low
$6.99

Profitability

Operating margin
-130.2%
Net margin
-140.3%
EBITDA margin
-109.8%
ROE
1971.4%
ROCE
-86.9%
ROIC
-475.1%
ROA
-46.7%
Asset turnover
0.33

Growth

Revenue
$81.4M
Revenue growth, 1Y
144.6%
Revenue CAGR, 3Y
72.3%
Net profit growth, 1Y
-22.7%
Free cash flow
-$50.6M

Solvency

Current ratio
0.75
Debt / Equity
-15.31
Debt / Assets
0.36
CFO / Net profit
0.41
Cash / Market cap
7.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$81.4M
Cost of revenue$4.8M
Gross profit$76.5M
Operating expenses$182.5M
Research and development$129.6M
Selling, general and administrative$52.9M
Operating income-$106.0M
Interest and other-$8.2M
Pretax income-$114.2M
Tax and other$0.00
Net income-$114.2M

Revenue and net profit

Revenue grew 144.6% in FY2025; net profit is the dashed line.

MeiraGTx Holdings plc revenue and net profit by fiscal year
MeiraGTx Holdings plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$15.9M-$129.6M
FY2023$14.0M-$84.0M
FY2024$33.3M-$147.8M
FY2025$81.4M-$114.2M

Cash flows

FY2025: -$46.4M from operations, -$50.6M free after investment (dashed).

MeiraGTx Holdings plc operating and free cash flow by fiscal year
MeiraGTx Holdings plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$73.1M-$118.1M
FY2023-$105.4M-$125.5M
FY2024-$104.5M-$109.5M
FY2025-$46.4M-$50.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$81.4M+144.6%1Y
EBITDA
-$89.4M
Net profit
-$114.2M
Cash from operations
-$46.4M
Free cash flow
-$50.6M
Revenue CAGR, 3Y
72.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$81.4M-$89.4M-$114.2M-$50.6M1971.4%+144.6%-22.7%

Monthly returns

Month-by-month returns of MGTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$244.4M
Liabilities$250.2M
Equity-$5.8M
Paid-in capital$808.0M
Retained earnings-$816.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MGTX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. MeiraGTx Holdings plc (this company)11.2x

Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
MeiraGTx Holdings plcMGTXthis company$886.3M-7.8x-153.0x1971.4%-10.2x
ARS Pharmaceuticals, Inc.SPRY$900.7M-5.3x7.9x-149.9%-5.7x
Annexon, Inc.ANNX$892.9M-4.3x4.2x-97.7%-3.5x
Pacira BioSciences, Inc.PCRX$892.0M126.9x1.3x1.0%8.7x
Xencor, Inc.XNCR$890.4M—1.4x-14.5%—
Cullinan Therapeutics, Inc.CGEM$886.8M-4.0x2.2x-53.8%-3.3x
Jade Biosciences, Inc.JBIO$875.6M—-18.7x-38.3%—
Certara, Inc.CERT$872.7M-547.2x0.8x-0.2%9.7x
Talkspace, Inc.TALK$871.1M111.8x7.4x6.7%129.1x
Peer median—-4.2x1.8x-26.4%2.7x

Year-to-date ROI

MGTX since 1 January, against earlier years.

Historical volatility

MGTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

MeiraGTx Holdings plc operating margin by fiscal year
MeiraGTx Holdings plc operating margin by fiscal year
DateOperating margin
FY2022-730.9%
FY2023-977.6%
FY2024-493.4%
FY2025-130.2%
LineFY2025
Cost of revenueCost Of Revenue$4.8M
Gross profitGross Profit$76.5M
Operating expensesOperating Expense$182.5M
Research and developmentResearch And Development$129.6M
Total expensesTotal Expenses$187.4M
Pretax incomePretax Income-$114.2M

Learn while you research

Academy chapters picked for MeiraGTx Holdings plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing145% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →